To include your compound in the COVID-19 Resource Center, submit it here.

Making Merrimack

Cancer play Merrimack has Fidelity, Fred Alger, TPG-Axon as investors before IPO

Merrimack Pharmaceuticals Inc. made its highly anticipated entrance into the biotech IPO queue late last week when the oncology play filed to raise up to $172.5 million.

The company already had raised $191.3 million in equity prior to a $77 million series G round that

Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE